Skip to Content
 

VICC toll-free number 1-877-936-8422

Skin Cancers and Melanoma

The melanoma program comprises of a diverse group of clinical and laboratory scientists with one common goal: Advancement of the treatment of melanoma.

Clinical Trials for Skin Cancers and Melanoma

12 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCMEL15137

07/21/2015

Characterizing the Cardiometabolic Implications of Immune Therapy

Basic Science

VICCMEL15148

03/13/2014

Investigating Immune Responses in Patients with Advanced Melanoma Treated with Immune-Based Therapy

Basic Science

VICCMEL09109

06/03/2010

Storage and Research Use of Human Biospecimens from Melanoma Patients and Clinical Testing for the Assignment of Therapy

Basic Science

VICCMEL0287

05/06/2003

Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository

Other

VICCMEL14103

08/17/2015

A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials

Treatment

VICCPHI1634

08/30/2016

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

Treatment

ECOGMELEA6141

05/10/2016

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Treatment

VICCPHI1531

03/01/2016

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

Treatment

ECOGMELS1404

12/01/2015

A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Treatment

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Treatment

VICCMEL1471

02/04/2015

A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

Treatment

VICCMEL1457

01/19/2015

A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations